Prevention and treatment of synucleinopathic disease
CA 2503561 C · Owner: Janssen Alzheimer Immunotherapy · Inventors: Masliah, Eliezer; Schenk, Dale B.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases including Lewy bodies of alpha-, synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 31, 2003 and granted December 29, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 31, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 31, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.